Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PTX-100 Monotherapy in Relapsed or Refractory Cutaneous T-Cell Lymphoma
NCT06854653Phase 2Recruiting
- Sponsor
- Prescient Therapeutics
- Start
- Mar 2025
- Primary completion
- Jan 2028
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, open-label trial of PTX-100 in cutaneous T-cell lymphoma (CTCL) (3 arms), sponsored by Prescient Therapeutics. Primary endpoint: Objective Response Rate at 18 months. Started Mar 2025; status: recruiting.
02
Drugs
PTX-100
03
Conditions
cutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on NCT06854653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06854653.